LONDON MARKET CLOSE: Stocks in green as US manufacturing surprises
15th Jan 2026 17:00
(Alliance News) - Stock prices in London closed higher on Thursday, after a surprise drop in US jobless claims. Read More
(Alliance News) - Stock prices in London closed higher on Thursday, after a surprise drop in US jobless claims. Read More
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday: Read More
(Alliance News) - Stock prices in London opened lower on Wednesday, as the FTSE 100 retreated from a record high, as oil firms BP and Shell weighed on the blue-chip index. Read More
(Alliance News) - GSK PLC on Wednesday reported positive developments with its shingles vaccine and its potential treatment for chronic hepatitis B, as it secured a presentation approval and announced positive data. Read More
(Alliance News) - Blue chips continued their strong start to the year on Tuesday with the FTSE 100 hitting a new record led by gains in retailer Next and drug stocks, GSK and AstraZeneca. Read More
(Alliance News) - GSK PLC on Tuesday said depemokimab, sold under the brand name Exdensur, has been approved by Japan's Ministry of Health, Labour and Welfare for severe asthma and chronic rhinosinusitis with nasal polyps. Read More
(Alliance News) - GSK PLC on Monday said mepolizumab, sold under the brand name Nucala, has been approved in China for use in adults with chronic obstructive pulmonary disease. Read More
(Alliance News) - Balfour Beatty sells ten UK assets for GBP87 million, Wizz Air and Ryanair report growth in passenger numbers for December, while Auction Technology Group rejects 11 takeover proposals from FitzWalter Capital. Read More
(Alliance News) - The FTSE 100 drifted lower on Wednesday in lacklustre trading ahead of the Christmas break, although a chunky disposal by BP brought some life to proceedings. Read More
(Alliance News) - Stock prices in London opened modestly lower on Wednesday, during a shortened trading session ahead of the Christmas holiday break. Read More
GSK PLC - London-based pharmaceuticals firm - Announces agreement with the US government to lower the cost of prescription medicines for American patients, including GSK's portfolio for respiratory conditions such as asthma and COPD. Says it will lower the price of certain medicines in Medicaid and "launch new products with a more balanced pricing approach", and will make most of its inhaled respiratory portfolio and other products available to patients on a direct purchasing platform with savings of up to 66%. Furthermore, it intends to further support the US supply chain for critical medicines by securing a reserve of albuterol, the active ingredient used in many inhalers to relieve the symptoms of asthma and COPD, for the US. Read More
(Alliance News) - Stock prices in London closed in the green on Thursday, following the Bank of England's decision to cut rates and a hold from the European Central Bank. Read More
(Alliance News) - GSK PLC on Wednesday said its Exdensur treatment, depemokimab, for severe asthma has been approved by the US Food & Drug Administration. Read More
(Alliance News) - GSK PLC on Monday said Exdensur has been approved in the UK, for the treatment of asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps. Read More
(Alliance News) - GSK PLC on Friday said the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended the approval of depemokimab in two indications. Read More
(Alliance News) - GSK PLC on Friday said European regulators have recommended broadening the indication for its Arexvy vaccine to all adults aged 18 and older. Read More
(Alliance News) - Stocks were called to open higher in London on Friday, as the Office for National Statistics reported that the UK economy unexpectedly shrank in October. Read More
GSK PLC - London-based pharmaceuticals firm - US Food & Drug Administration approves a supplemental new drug application for gepotidacin as an oral option for adult and paediatric patients from 12 years of age for the treatment of uncomplicated urogenital gonorrhoea. This follows the US FDA approval of gepotidacin earlier this year as an oral treatment for female adult and paediatric patients 12 years of age and older with uncomplicated urinary tract infection. The application was based on positive results from the Eagle-1 phase III trial which demonstrated that gepotidacin was non-inferior to standard of care combination treatment for gonorrhoea. The trial also supported the safety and tolerability profile of gepotidacin, with no serious drug related adverse events observed in either the gepotidacin or the comparator arm. The most common reported adverse reactions were mild to moderate gastrointestinal events. Read More
(Alliance News) - Outgoing GSK PLC Chief Executive Officer Emma Walmsley has said the US is the best place to invest, in the latest blow to Britain's pharmaceutical sector, after a raft of drugs firms have scrapped or paused plans to invest in the UK. Read More